Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapy
Responses to botensilimab/balstilimab were durable, with 80% ongoing at data cut-off and median duration of response not reached
Global, randomized Phase 2 study of botensilimab/balstilimab in MSS CRC to begin this year
Agenus to host webcast today at 10:00 AM EDT
The Company will host an investor webcast today at 10:00 AM EDT to review these data. Participants may register here, or on the Investors section of the Agenus website at investor.agenusbio.com. The webcast will include presentations by the below speakers and will be followed by a Q&A session:
Steven O’Day, M.D., Agenus’ Chief Medical Officer
Dr. Anthony El-Khoueiry, M.D., Associate Director of Clinical Research at the USC Norris Comprehensive Cancer Center, Keck School of Medicine
Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital, and
Dr. Heinz-Josef Lenz, M.D., Professor of Medicine and J. Terrence Lanni Chair in Gastrointestinal Cancer Research, Keck School of Medicine
Following the webcast, an archived version will be available on the Agenus website.
https://finance.yahoo.com/news/agenus-shows-unprecedented-activity-botensilimab-110000051.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.